Company Filing History:
2 out of 272 
2 out of 62 
Years Active: 2014-2016
Title: Lilia Koriazova: Innovating Monoclonal Antibodies for Poxvirus Research
Introduction
Lilia Koriazova is an accomplished inventor based in San Diego, California. She has made significant contributions to the field of immunology with her research and innovations. With two patents to her name, Koriazova’s work focuses on developing monoclonal antibodies specific to the vaccinia virus, showcasing her dedication to advancing medical science.
Latest Patents
Koriazova's latest patents, titled "Vaccinia virus H3L and B5R specific monoclonal antibodies and methods of making and using same," highlight her innovative approach to targeting specific proteins in poxviruses. These patents describe antibodies that specifically bind to the B5R envelope protein and the H3L envelope protein of poxvirus, as well as their subsequences and combinations. This groundbreaking invention holds promise for therapeutic applications and further understanding of poxvirus pathogenesis.
Career Highlights
Throughout her career, Lilia Koriazova has worked with prestigious organizations such as Kyowa Hakko Kirin Co., Limited and the La Jolla Institute for Allergy and Immunology. Her tenure at these institutions has enabled her to collaborate with leading scientists and contribute to various research initiatives, solidifying her reputation in the field.
Collaborations
In her journey, Koriazova has had the opportunity to collaborate with notable coworkers, including Shinichiro Kato and Steve Granger. Such collaborations have enhanced her research capabilities, allowing her to explore innovative solutions and further her contributions to the scientific community.
Conclusion
Lilia Koriazova stands as a prominent figure in the field of immunology. With her two patents related to monoclonal antibodies for poxvirus, she embodies the spirit of innovation and dedication to scientific advancement. Her work not only contributes to the understanding of viral mechanisms but also paves the way for potential therapeutic advancements.